

0.624 mg/dL for each additional ($p=0.017$) year of age and triglycerides increased by 1.417 mg/dL for each additional ($p=0.041$) year of age. Changes in HbA1c, total cholesterol and HDL-cholesterol over time were not significantly correlated with patient age or time since diagnosis. Therefore, health economic modelers may assume that these parameters remain stable over time. Sensitivity analyses were performed to address the potential mislabeling of T2DM as T1DM patients. **CONCLUSIONS:** These results provide relevant inputs for the progression of physiological parameters to model the economic and clinical impacts of T1DM therapies over time.

PDB30

TREND IN PREVALENCE AND DISTRIBUTION OF DIABETES MELLITUS TYPE I AND TYPE II IN THE NETHERLANDS

Overbeek JA¹, Penning FJA¹, van Dongen E², Herings RMC¹

¹PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²Novo Nordisk B.V., Alphen a/d Rijn, The Netherlands

OBJECTIVES: To quantify the trend in prevalence and distribution of diabetes mellitus (DM) type I (T1DM) and type II (T2DM) in the Netherlands. **METHODS:** Using the General Practitioner Database and the Out-patient Pharmacy Database of the PHARMO Database Network, the trend in prevalence of DM and distribution of T1DM and T2DM from 2005 to 2012 was assessed. Per year, patients with ≥ 2 anti-diabetic drug dispensings within 6 months were selected as DM patient. Patient numbers were extrapolated to the Netherlands to determine prevalence of DM. For all patients, diabetes treatment at September 30 of that year was assessed. For patients with a GP recorded diagnosis for T1DM or T2DM, distribution of T1DM/T2DM was stratified by treatment. This distribution of DM type by treatment was applied to the treatment of patients with no GP recorded DM type to assess the distribution of T1DM/T2DM. **RESULTS:** The prevalence of DM in the Netherlands increased from 38 per 1000 males and 40 per 1000 females in 2005 to 54 per 1000 males and 52 per 1000 females in 2012. The distribution of T1DM versus T2DM among patients with DM changed from 15% versus 85% in 2005 to 8% versus 92% in 2012. Among patients with T1DM mean (\pm SD) age decreased from 48 (± 22) years in 2005 to 44 (± 22) years in 2012. Among patients with T2DM mean age increased from 63 (± 12) years in 2005 to 67 (± 12) years in 2012. **CONCLUSIONS:** This study describes the epidemiology of DM in the Netherlands over 2005–2012. Prevalence of DM increased and relatively more patients were diagnosed with T2DM. These changes can be explained by the ageing Dutch population, better survival, more obesity and early detection of T2DM. Furthermore, introduction of the T2DM care program in 2005 probably has led to a better registration of T2DM patients.

PDB31

FACTORS ASSOCIATED WITH HOSPITALIZATION OF TYPE 2 DIABETIC PATIENTS WITH HYPOLYCEMIC EPISODES ASSISTED AT EMERGENCY DEPARTMENTS

Conceição J¹, Laires P¹, Araújo F², Dores J³, Vicente V⁴, Silva C⁴, Carr R⁵, Brodovitz K⁶, Radican L⁷, Nogueira AM¹

¹Merck Sharp & Dohme, Oeiras, Portugal, ²Hospital Beatriz Ângelo, Loures, Portugal, ³Hospital de Santo António, Porto, Portugal, ⁴Eurotrial, Lisbon, Portugal, ⁵Merck Sharp & Dohme, Ballerup, Denmark, ⁶Merck & Co., North Wales, PA, USA, ⁷Merck & Co., Inc., Whitehouse Station, NJ, USA **OBJECTIVES:** HIPOS-ER is an observational, cross-sectional, multicenter study to describe the patient population of Type 2 diabetics treated with an anti-hyperglycemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic event. In this analysis we aim to identify factors associated with hospitalization following admission in the ER. **METHODS:** The study enrolled patients from 7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 2014). Sociodemographic and clinical data were collected at the ER and patients who required hospital admission were followed up. Multiple logistic regression was used to identify factors associated with hospitalization. **RESULTS:** A total of 238 patients were enrolled of whom 105 (44%) were hospitalized. These patients were older than non-hospitalized (mean: 78 years vs. 75 years; $p=0.020$). About half of the hospitalized patients were on secretagogue based regimen. Glasgow coma scale score was not statistically different between hospitalized and non-hospitalized patients ($p=0.270$), however hospital admissions showed lower values of the lowest recorded plasma/capillary glycemia (mean: 35 mg/dL vs. 41 mg/dL; $p=0.004$) and a higher prevalence of hypoglycemia complications (26% vs. 9%; $p<0.001$). Obesity and higher plasma capillary glycaemia level are associated with a lower risk of hospitalization (OR=0.29 and OR=0.96, respectively; $p<0.010$) while treatment with secretagogue based regimen, presence of hypoglycemia complications and other atherosclerotic disease are associated with a higher risk (OR=5.71, OR=3.89 and OR=2.87, respectively; $p<0.010$). **CONCLUSIONS:** Almost half of the patients with diabetes suffering a hypoglycemic event who required medical assistance at the ER were hospitalized. Presence of some factors may increase the risk of these expensive cases which are also surrogates for the potential severity of the hypoglycemic episodes. Identification of these predictors may help assist physicians at the emergency room to proactively act upon patients at higher risk of hospitalization and generate substantial health and economic gains to the hospitals.

PDB32

THE IMPACT OF TREATMENT OF THYROID DISEASE IN PREGNANT WOMEN TO THE OUTCOME OF GIVING BIRTH

Ferenczy M¹, Póhr K¹, Lőcsei Z², Oláh A³, Boncz I⁴, Karácsony I¹, Salamonné Toldy E²

¹University of Pécs, Szombathely, Hungary, ²Markusovszky University Teaching Hospital, Szombathely, Hungary, ³University of Pécs, Pécs, Hungary, ⁴Faculty of Health Sciences, University of Pécs, Pécs, Hungary

OBJECTIVES: The most common endocrine clinical symptom is thyroid disease which has impact to pregnant women and fetus. Leading international references about its treatments are well known, there is no relevant experiences in the Hungarian context. Aim of this study is to inspect the thyroid disease and impact of its treatment to outcome of pregnancy. **METHODS:** Survey was carried out at Markusovszky Hospital in Vas County, Hungary. Retrospective study made by data analysis of pregnant patient with thyroid disease, including hormone parameters,

medications and obstetric medical history. Set-up was non-random, convenience sampling with 40 women's data with mean age 33.7 ± 3.6 , between August 2013 – February 2014. Friedmann ANOVA and t-test was applied for analysis with software Statistics for Windows. **RESULTS:** Progresses the gestation period significant reduction of TSH values was observed in hypothyroid patients ($p=0.0075$). Comparing successive TSH values of the individual patients showed the same significant difference. Significant negative correlation was founded between TSH value and thyroxine dose in group of hypothyroid patients ($r=-0.35$; $p<0.05$). Premature birth and other obstetric complications occurred more frequently in the thyrotoxic group, especially among older women giving birth. **CONCLUSIONS:** In case of hypothyroid pregnant with increasing dose of thyroxine the TSH levels are well balanced, and obstetric complications did not occur, while in hyperthyroid patients can be reported obstetric complications in addition to proper care.

DIABETES/ENDOCRINE DISORDERS – Cost Studies

PDB33

BUDGET IMPACT ANALYSIS OF ADDING DAPAGLIFOZIN TO THE THERAPY OF DIABETES MELLITUS TYPE 2 IN BULGARIA

Manova M¹, Petkova E¹, Yordanova S¹, Petkova V¹, Petrova G²

¹Medical University of Sofia, Faculty of Pharmacy, Sofia, Bulgaria, ²Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria

OBJECTIVES: Dapagliflozin is a highly potent, selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2) and is approved for the treatment of T2DM in adults. Diabetes type 2 is one of the most prevalent chronic diseases that can lead to serious complications and disability. The largest costs are those associated with hospitalizations due to the complications, the prevention of which requires a good glycemic control. The objective of the study is to estimate the budget impact of adding dapagliflozin to the therapy of type 2 diabetes in Bulgaria. **METHODS:** The budget impact model was used from the payer perspective for population 7 284 552 people, and out of them 450000 are type 2 diabetics. The retail pharmacy prices were used from the Positive Drug List. Official IMS data for antidiabetic medicines were incorporated in the model. Net budget impact is presented as costs per-member per-month (PMPM) and costs per-patient per-year (PPPY). **RESULTS:** An increase in the estimated net budget impact from 70 592 € first year to 1 290 716 € for the fifth year was observed after adding dapagliflozin to T2DM therapy, with a cumulative net budget impact of 3 258 047 €. PMPM and PPPY costs show minimal growth with respective cumulative values of 0.06 € and of 65.63 €. The cost for dapagliflozin therapy is comparable to that of DPP-4 inhibitors and is lower than the cost of treatment with a GLP-1. **CONCLUSIONS:** The results show that adding dapagliflozin to standard therapy will lead to minimal increase in the diabetes type 2 budget in Bulgaria. This increase is considered acceptable in terms of better glycemic control with safe and effective therapy for diabetes type 2.

PDB34

ASSESSMENT OF THE ECONOMIC VALUE OF DPP-4 INHIBITOR ALOGLIPTIN COMPARED WITH SITAGLIPTIN, SAXAGLIPTIN, AND LINAGLIPTIN

Pedrazzoli M¹, Pasquini F¹, Minda K²

¹LSC Lifesciences Consultants, Milan, Italy, ²Takeda Pharmaceuticals, Glattbrugg-Opfikon (Zurich), Switzerland

OBJECTIVES: Objective of this study is to provide additional evidence for decision making to payers assessing health care resource utilization, economic impact, and cost-effectiveness of DPP-4 inhibitor alogliptin compared with sitagliptin, saxagliptin and linagliptin, for the treatment of type-2 diabetes mellitus (T2DM). **METHODS:** 29 comparable, randomized clinical trials were selected out of a panel of 58 studies. 6 different clinical endpoints (efficacy and safety) were compared across 5 different combinations: DPP-4 Monotherapy, +metformin (MET), +sulfonylurea (SU), +thiazolidinedione (TZD), +insulin (INS). For each endpoint and combination, alogliptin clinical endpoints were compared with respective average endpoints of other DPP-4s. Differentials were calculated after adjustment for baseline characteristics. Each endpoint was associated with the impact on patient outcomes and related health care costs (T2DM-related complications, treatment escalation, costs associated with adverse events: hypoglycemia, cardiovascular mortality, hospitalization due to heart failure, lipids profile) obtained from published data. Economic value saving of alogliptin was calculated and compared to the other DPP-4s. **RESULTS:** The proportion of patients at target (HbA1c<7%) as well as the reduced need for treatment escalation with alogliptin could generate annual savings for a health care system of €69.62 and €22.97 per patient-year, respectively. Improved lipids profile and proven CV safety of alogliptin can generate savings of €40.86 and €21.47 per patient-year, respectively. Impact of lower hypoglycemia and increased adherence with fixed dose combinations with TZD may generate additional savings (€1.53 and €1.60/ patient-year, respectively). **CONCLUSIONS:** This study suggests that alogliptin could generate significant savings for a Healthcare System, even at price parity with other DPP-4s, thanks to its efficacy and safety profile, particularly in the widely used DPP-4+MET combination. Total savings of up to €158 per patient-year compare favorably with an overall cost of treatment with a DPP-4i ranging from €350 to €481 per patient-year.

PDB35

COST-EFFECTIVENESS ANALYSIS OF AUTOCODED AND MANUALLY CODED BLOOD GLUCOSE METERS IN DIABETES TREATMENT

Yagudina R, Kulikov A, Babiy V

I. M. Sechenov First Moscow State Medical University, Moscow, Russia

OBJECTIVES: To conduct a cost-effectiveness assessment of glucose meters (manually coded and autocoded) in diabetes treatment in the Russian Federation. **METHODS:** Clinical effectiveness assessment was based on the results of modeling of the treatment of patients with diabetes that use manually coded and autocoded blood glucose meters. Cost analysis included assessment of direct and indirect costs that can be

associated with manually coded meters (model 1 and model 2) and autocoded meters (model 3). Cost data was based on median prices for medicines, devices, medical services in National health care system in the Russian Federation. **RESULTS:** Annual direct costs per patient in the group of manually coded glucose meters were 1533 euro (model 1) and 1574 euro (model 2), and in the group of autocoded meters were 1557 euro (model 3). Annual total costs per patient in the group of manually coded glucose meters were 2992 euro (model 1) and 2921 euro (model 2), and in the group of autocoded meters were 3034 euro (model 3). Cost-effectiveness ratio for autocoded meters was 1875 euro (model 3) and for manually coded meters was 1954 euro (model 1) and 1982 euro (model 2) per 1 LYG, respectively (discounted at 3%). Budget impact analysis showed that use of autocoded meters (model 3) instead of manually coded (model 1 and model 2) leads to the annually cost savings of 33 euro and 53 euro per patient, respectively (discounted at 3%). **CONCLUSIONS:** Obtained results approve the use of autocoded blood glucose meters instead of manually coded blood glucose meters to administrate blood glucose level as part of intensive glucose-lowering therapy from a pharmacoeconomic point of view.

PDB36

HEALTH ECONOMIC IMPACT OF BARIATRIC SURGERY REVISITED: STRUCTURED REVIEW OF LITERATURE AND HEALTH TECHNOLOGY ASSESSMENTS

Chawla AS¹, Tao C², Faulkner EC³, Hsiao CW⁴, Patkar AD⁵, Romney M⁶
¹Quintiles Consulting, Durham, NC, USA, ²Quintiles Consulting, Cambridge, MA, USA, ³Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA, ⁴Johnson and Johnson Medical Companies, Markham, ON, Canada, ⁵Ethicon, Inc, Somerville, NJ, USA, ⁶Jefferson School of Population Health, Philadelphia, PA, USA

OBJECTIVES: The costs of obesity are staggering, accounting for 2-6% of global health care costs. The health economic benefits of bariatric surgery while notable, are multi-faceted, resulting in heterogeneous reporting in the literature. To that end, this study seeks to 1) highlight available evidence of the health economic impact of bariatric surgery, and to 2) identify key gaps in current evidence that may influence uptake by health care systems. **METHODS:** Evidence of the health economic impact was collated from 107 scientific articles, of which 19 were systematic reviews, published between 2010-March 2014 and archived in MEDLINE and PubMed. Additionally, HTAWatch identified 10 HTAs, largely from North America and the EU that evaluated economic benefits. **RESULTS:** In all countries where evaluated, bariatric surgery was cost-effective compared to non-surgical therapy. The surgery was likely more cost-effective with higher patient BMI and with comorbidities, especially for BMI > 40kg/m², although estimates varied. Furthermore, resolution of underlying comorbidities resulted in reduced utilization of health care services, pharmaceutical utilization, and improved work productivity, among others, resulting in cost saving of 60-70% relative to standard care over a 3-year period. Importantly, time to break even was typically in the 4-7 years range, and was shorter for patients with Type 2 Diabetes Mellitus (T2DM) and with BMI > 40kg/m², typically in the 1.25-5 year range. Three key evidence gaps were identified: few studies computed long-term cost-effectiveness; no head-to-head trials have directly compared different surgical procedures; and heterogeneity across populations and health system impede meta-analyses of patient outcomes such as QoL and long-term health benefits. **CONCLUSIONS:** Although heterogeneous, reports of health economic benefits of bariatric surgery indicate an overall positive trend, largely via reduction of health resource utilization. To firmly establish its impact, future studies need to conduct head-to-head comparisons, determine optimal patient populations, and employ standard clinical endpoints to demonstrate real world, long-term benefits.

PDB37

ASSOCIATION OF CHANGES IN BODY WEIGHT WITH HEALTH CARE COSTS AMONG PATIENTS WITH NEWLY-DIAGNOSED TYPE-2 DIABETES IN SWEDEN

Sabale U¹, Bodegård J¹, Sundström J², Svernlund B³, Östgren CJ⁴, Nilsson P⁵, Johansson G³, Henriksson M¹

¹AstraZeneca Nordic-Baltic, Södertälje, Sweden, ²Uppsala University, Uppsala, Australia, ³Uppsala University, Uppsala, Sweden, ⁴Linköping University, Linköping, Sweden, ⁵Lund University, Malmö, Sweden

OBJECTIVES: Type 2-diabetes and excess weight incur large costs to health care systems, but the association between weight progression in diabetes and health care costs is unknown. We investigated those relations using real world data in a sample of newly diagnosed diabetes patients in Sweden by using repeated body mass index (BMI) measurement and health care resource utilization data. **METHODS:** Patients with a BMI (kg/m²) measure at diagnosis and subsequent BMI measures at 12,24,36,48, and 60 months were identified from a previously conducted register study. Individuals were classified into three groups based on their BMI change over 5 years: increase (>1 BMI unit increase), decrease (>1 BMI unit decrease), and stable (≤1 BMI unit change). Each group was stratified by BMI at diagnosis (BMI 18-25; 25-30; ≥30). Health care costs for each group were estimated by applying Swedish unit costs to the health care resource data extracted from electronic patient journals and a national patient register. **RESULTS:** The study included 903 T2D patients (women, 43%; mean age, 62; mean HbA1c, 6.78%; mean BMI, 30.9). The BMI increased, decreased, or remained stable in 178 (20%), 387 (43%), and 338 (37%) patients, respectively. Among patients with baseline BMI 18-25 (n=104), the five year cumulative health care costs were €13,695, €9,059, €8,936, in the increase, decrease, and stable group, respectively. Corresponding figures were €11,470, €7,950, €8,683 for patients with baseline BMI 25-30 (n=321), €14,387, €9,465, and €9,302 for patients with BMI ≥30 (n=478). **CONCLUSIONS:** In newly diagnosed diabetes, an increase in BMI lead to increased health care costs, irrespective of baseline BMI. Linking registry data on repeated BMI measurements and health care utilization is a valuable approach to investigate the association between weight changes and costs. Costs of interventions that maintain weight in patients with diabetes should be considered in the context of costs associated with weight gain.

PDB38

EFFECT OF SMOKING STATUS ON HEALTH CARE COSTS IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE NESTED CASE-CONTROL ECONOMIC STUDY IN ROUTINE CLINICAL PRACTICE

Sicras Mainar A¹, Rejas Gutiérrez J², Navarro Artieda R³, Ibáñez Nolla J⁴, De Lossada Juste A⁵

¹Badalona Serveis Assistencials SA, Badalona (Barcelona), Spain, ²Pfizer S.L.U., Alcobendas/Madrid, Spain, ³Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain, ⁴Badalona Serveis Assistencials, Badalona, Spain, ⁵Pfizer, S.L.U., Alcobendas/Madrid, Spain

OBJECTIVES: Smoking in diabetics is associated with a worse prognosis and vascular complications. The available evidence on health care resources utilization and associated costs in diabetics who smoke is limited or nonexistent. Thus, the objective was to compare health care resource utilization and costs according to smoking status in patients with type 2 diabetes in clinical practice. **METHODS:** A retrospective cohort nested case-control study was designed. Cases were current smokers, while two types of controls (former smokers and never smokers) were matched, two controls per case, for age, sex, duration of diabetes, and burden of comorbidity using data from electronic medical records. Non-institutionalized diabetics, both genders, age >18 years, seen consecutively over a 5-year period before the index date were enrolled. Perspective of both the National Health System and the Society were chosen and costs of health care resource utilization and loss of productivity due to sick leaves were compared among groups using a linear general model with covariates. **RESULTS:** A total of 2,490 records were analyzed: 498 from cases, 996 from former smokers, and 996 from never smokers. Mean age was 63.4 years (64.9% male). Smokers had higher HbA1c (7.4% vs. 7.2% and 7.2%, respectively, p = 0.013) and a lower degree of metabolic control (49.2% vs. 54.7% and 55.8%, p = 0.036). Smokers had higher average annual costs (€3,583) than former smokers (€2,885) and never smokers (€2,183), p < 0.001. Mean annual health care cost saving per patient was associated with elapsed time of quitting smoking from €950 in subjects quitting smoking 2-year to €1173 5-year or more, p < 0.05. **CONCLUSIONS:** Diabetic smoker patients had lower metabolic control, higher health resource utilization, and more sick leave, resulting in higher health care costs and lost productivity compared with both former and never diabetic smokers. Health care cost-savings was associated with elapsed time from quitting smoking.

PDB39

EVALUATION OF POTENTIAL WASTE OF GROWTH HORMONE ACROSS AVAILABLE GROWTH HORMONE PEN DEVICES AND AN ELECTRONIC GROWTH HORMONE DELIVERY DEVICE

Locklear J¹, Edwards N², Phillips AL¹

¹EMD Serono, Inc., Rockland, MA, USA, ²Health Services Consulting Corporation, Boxborough, MA, USA

OBJECTIVES: The aim of this analysis was to estimate the potential GH waste per patient with pen devices and the easypod® device, and to quantify the potential economic impact of expected GH waste from patient and health care organization perspectives. **METHODS:** A Waste Calculator Model was developed to examine GH waste. All somatropin products available in pen or electronic devices were included. The user may define distribution across cartridges sizes. The mechanical/priming loss applied to each product was based upon each product's prescribing information and/or instructions for use. The base case model utilizes a US patient daily dose of 1.4 mg. The model assumes that the easypod® dose adjustment feature is activated by the clinician (±25%). Model assumes that 42.6% of caregivers discard the remaining amount left in the cartridge (eg waste) if less than a full dose. Annual amount of GH waste (mg, cartridges, dollars) per patient and per population (based on US national market shares) for each pen/device is reported. **RESULTS:** The expected annual amount of waste per patient was lowest for easypod®. The expected annual amount of waste per patient was highest for Omnitrope®. The expected annual amount of waste ranged from 0 to 38.9mg per patient per year, which is equal to 0 to 8 cartridges per patient per year and/or 0 to \$2,935 per patient per year. For a patient population of 100 GH-treated patients, the annual amount of waste is estimated at 2,009 mg, which can be translated into approximately 342 cartridges or about \$162,000 per year. The results in GH waste fluctuated depending upon daily dose, cartridge size, and dose spread assumptions. **CONCLUSIONS:** The expected annual amount of GH waste evaluated in this Waste Calculator was lowest with easypod®. Cost of GH waste can be an important consideration when evaluating GH delivery devices.

PDB40

BENEFIT OF POSITIVE AIRWAY PRESSURE (PAP) THERAPY IN SLEEP APNOEA (SA) PATIENTS WITH TYPE II DIABETES MELLITUS (T2DM) IN GERMANY: A RETROSPECTIVE COMPARATIVE COHORT ANALYSIS BASED ON A STATUTORY HEALTH INSURANCE DATABASE

Doess A¹, Zucca F², Woehle H³, Brueggemann B⁴

¹ResMed Germany Inc., Martinsried, Germany, ²HGC GesundheitsConsult, Duesseldorf, Germany,

³ResMed Science Center, Martinsried, Germany, ⁴Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité - Universitätsmedizin Berlin, Berlin, Germany

OBJECTIVES: It is estimated that the prevalence of moderate-to-severe SA (apnoea-hypopnoea index >15/h) is 10%. Patients with T2DM have a particularly high incidence of SA. T2DM and SA influence the development and progression of each other. This study investigated the effects of PAP therapy in SA patients with T2DM on all-cause mortality and cost of illness (COI) in Germany from a statutory health insurance (SHI) perspective. **METHODS:** A total of >4 million individuals covered by the SHI database were analysed (=5% of the German SHI population). PAP therapy was initiated in 4,068 patients with SA (PAP group). Propensity score matching was used to define a control group (CG) of 4,068 SA patients matched for age, sex, risk factors/aetiology, region and medication who received usual care (no PAP). Of these, 1,280 patients in the PAP group and 1,186 patients in the CG had comorbid T2DM. This subgroup of patients was followed for 3 years after initiation of PAP therapy. **RESULTS:** Total COI was higher in the PAP group versus CG in year 1 (€8,105 vs €7,037, p < 0.0001). After 2 years' follow-up, COI in the PAP group decreased but remained higher versus CG (€6,842 vs €6,625, p < 0.001). After 3 years, PAP group COI